BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 15574370)

  • 1. S100A10, annexin A2, and annexin a2 heterotetramer as candidate plasminogen receptors.
    Kwon M; MacLeod TJ; Zhang Y; Waisman DM
    Front Biosci; 2005 Jan; 10():300-25. PubMed ID: 15574370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phospholipid-associated annexin A2-S100A10 heterotetramer and its subunits: characterization of the interaction with tissue plasminogen activator, plasminogen, and plasmin.
    MacLeod TJ; Kwon M; Filipenko NR; Waisman DM
    J Biol Chem; 2003 Jul; 278(28):25577-84. PubMed ID: 12730231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of the annexin A2 heterotetramer in vascular fibrinolysis.
    Madureira PA; Surette AP; Phipps KD; Taboski MA; Miller VA; Waisman DM
    Blood; 2011 Nov; 118(18):4789-97. PubMed ID: 21908427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of plasmin generation by S100A10.
    Miller VA; Madureira PA; Kamaludin AA; Komar J; Sharma V; Sahni G; Thelwell C; Longstaff C; Waisman DM
    Thromb Haemost; 2017 Jun; 117(6):1058-1071. PubMed ID: 28382372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RNA interference-mediated silencing of the S100A10 gene attenuates plasmin generation and invasiveness of Colo 222 colorectal cancer cells.
    Zhang L; Fogg DK; Waisman DM
    J Biol Chem; 2004 Jan; 279(3):2053-62. PubMed ID: 14570893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On the contribution of S100A10 and annexin A2 to plasminogen activation and oncogenesis: an enduring ambiguity.
    Bydoun M; Waisman DM
    Future Oncol; 2014 Dec; 10(15):2469-79. PubMed ID: 25525855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Annexin A2/S100A10 Complex: The Mutualistic Symbiosis of Two Distinct Proteins.
    Bharadwaj A; Kempster E; Waisman DM
    Biomolecules; 2021 Dec; 11(12):. PubMed ID: 34944495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of fibrinolysis by S100A10 in vivo.
    Surette AP; Madureira PA; Phipps KD; Miller VA; Svenningsson P; Waisman DM
    Blood; 2011 Sep; 118(11):3172-81. PubMed ID: 21768297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urokinase-type plasminogen activator stimulation of monocyte matrix metalloproteinase-1 production is mediated by plasmin-dependent signaling through annexin A2 and inhibited by inactive plasmin.
    Zhang Y; Zhou ZH; Bugge TH; Wahl LM
    J Immunol; 2007 Sep; 179(5):3297-304. PubMed ID: 17709546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell surface protease activation during RAS transformation: Critical role of the plasminogen receptor, S100A10.
    Madureira PA; Bharadwaj AG; Bydoun M; Garant K; O'Connell P; Lee P; Waisman DM
    Oncotarget; 2016 Jul; 7(30):47720-47737. PubMed ID: 27351226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of annexin II tetramer in plasminogen activation.
    Kang HM; Choi KS; Kassam G; Fitzpatrick SL; Kwon M; Waisman DM
    Trends Cardiovasc Med; 1999; 9(3-4):92-102. PubMed ID: 10578524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ANXA2/S100A10 Complex-Regulation of the Oncogenic Plasminogen Receptor.
    Bharadwaj AG; Kempster E; Waisman DM
    Biomolecules; 2021 Nov; 11(12):. PubMed ID: 34944416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of plasmin activity by annexin II tetramer.
    Fitzpatrick SL; Kassam G; Choi KS; Kang HM; Fogg DK; Waisman DM
    Biochemistry; 2000 Feb; 39(5):1021-8. PubMed ID: 10653646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasminogen activator inhibitor type 2 inhibits cell surface associated tissue plasminogen activator in vitro: potential receptor interactions.
    Lobov S; Croucher DR; Saunders DN; Ranson M
    Thromb Haemost; 2008 Aug; 100(2):319-29. PubMed ID: 18690354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Annexin A2-S100A10 heterotetramer is upregulated by PML/RARĪ± fusion protein and promotes plasminogen-dependent fibrinolysis and matrix invasion in acute promyelocytic leukemia.
    Huang D; Yang Y; Sun J; Dong X; Wang J; Liu H; Lu C; Chen X; Shao J; Yan J
    Front Med; 2017 Sep; 11(3):410-422. PubMed ID: 28687976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of annexin II in angiogenesis and tumor progression: a potential therapeutic target.
    Sharma MC; Sharma M
    Curr Pharm Des; 2007; 13(35):3568-75. PubMed ID: 18220793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endothelial cell annexin A2 regulates polyubiquitination and degradation of its binding partner S100A10/p11.
    He KL; Deora AB; Xiong H; Ling Q; Weksler BB; Niesvizky R; Hajjar KA
    J Biol Chem; 2008 Jul; 283(28):19192-200. PubMed ID: 18434302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p11 regulates extracellular plasmin production and invasiveness of HT1080 fibrosarcoma cells.
    Choi KS; Fogg DK; Yoon CS; Waisman DM
    FASEB J; 2003 Feb; 17(2):235-46. PubMed ID: 12554702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The biochemistry and regulation of S100A10: a multifunctional plasminogen receptor involved in oncogenesis.
    Madureira PA; O'Connell PA; Surette AP; Miller VA; Waisman DM
    J Biomed Biotechnol; 2012; 2012():353687. PubMed ID: 23118506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of the annexin A2 heterotetramer as a receptor for the plasmin-induced signaling in human peripheral monocytes.
    Laumonnier Y; Syrovets T; Burysek L; Simmet T
    Blood; 2006 Apr; 107(8):3342-9. PubMed ID: 16373665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.